Clene Inc., a clinical-stage biopharmaceutical company, announced a regulatory update following a constructive Type C meeting with the U.S. Food and Drug Administration (FDA). The FDA provided supportive feedback on Clene's proposed statistical analysis plan for neurofilament biomarker analysis in its NIH-sponsored Expanded Access Program, which supports nearly 200 ALS patients. The biomarker analyses are scheduled for early in the 4th quarter of 2025. Clene confirmed two additional FDA meetings for the 3rd quarter of 2025 to discuss ALS survival data and their multiple sclerosis $(MS)$ clinical development program. The company is on track to potentially submit a new drug application for ALS under the accelerated approval pathway by the end of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.